Targeting the CSF1/CSF1R signaling pathway: an innovative strategy for ultrasound combined with macrophage exhaustion in pancreatic cancer therapy.
| Autor: | Wang Q; Department of Ultrasound, Xichong People's Hospital, Nanchong, China., Wang J; Department of Internal Medicine, Guang'an Vocational & Technical College, Guang'an, China., Xu K; Department of Oncology, Chongqing General Hospital, Chongqing University, Chongqing, China., Luo Z; Department of Oncology, Chongqing General Hospital, Chongqing University, Chongqing, China. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in immunology [Front Immunol] 2024 Oct 02; Vol. 15, pp. 1481247. Date of Electronic Publication: 2024 Oct 02 (Print Publication: 2024). |
| DOI: | 10.3389/fimmu.2024.1481247 |
| Abstrakt: | Pancreatic cancer (PC) is a highly aggressive and lethal malignancy characterized by a complex tumor microenvironment (TME) and immunosuppressive features that limit the efficacy of existing treatments. This paper reviews the potential of combining ultrasound with macrophage exhaustion in the treatment of pancreatic cancer. Macrophages, particularly tumor-associated macrophages (TAMs), are crucial in pancreatic cancer progression and immune escape. Prolonged exposure to the immunosuppressive TME leads to macrophage exhaustion, reducing their anti-tumor ability and instead promoting tumor growth. The CSF1/CSF1R signaling pathway is key in macrophage recruitment and functional regulation, making it an effective target for combating macrophage exhaustion. Ultrasound technology not only plays a significant role in diagnosis and staging but also enhances therapeutic efficacy by guiding radiofrequency ablation (RFA) and percutaneous alcohol injection (PEI) in combination with immunomodulators. Additionally, ultrasound imaging can monitor the number and functional status of TAMs in real-time, providing a basis for optimizing treatment strategies. Future studies should further investigate the combined use of ultrasound and immunomodulators to refine treatment regimens, address challenges such as individual variability and long-term effects, and offer new hope for pancreatic cancer patients. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Wang, Wang, Xu and Luo.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|